Warning: The NCBI web site requires JavaScript to function. more...
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.
Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, Elvin K, Simard JF, Hansson LO, Lundberg IE, Larsson A, Svenungsson E.
Arthritis Res Ther. 2009;11(6):R186. Epub 2009 Dec 10.
Related citations
Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge.
Bultink IE.
Arthritis Res Ther. 2010;12(1):107. Epub 2010 Feb 22.
Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients.
Karadag O, Calguneri M, Atalar E, Yavuz B, Akdogan A, Kalyoncu U, Bilgen SA, Ozer N, Ertenli AI, Ovunc K, Kiraz S.
Clin Rheumatol. 2007 May;26(5):695-9. Epub 2006 Aug 15.
Cardiovascular risk and lupus disease.
Boucelma M, Haddoum F, Chaudet H, Kaplanski G, Mazouni-Brahimi N, Rezig-Ladjouze A, Brouri M, Berrah A.
Int Angiol. 2011 Feb;30(1):18-24.
Predictors of carotid atherosclerosis in systemic lupus erythematosus.
Maksimowicz-McKinnon K, Magder LS, Petri M.
J Rheumatol. 2006 Dec;33(12):2458-63. Epub 2006 Oct 1.
Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus.
Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J.
Scand J Rheumatol. 2008 Sep-Oct;37(5):352-9.
[Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
Fischer K, Brzosko M, Walecka A, Ostanek L, Sawicki M.
Pol Arch Med Wewn. 2007;117 Suppl:13-7. Polish.
Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus.
Bultink IE, Teerlink T, Heijst JA, Dijkmans BA, Voskuyl AE.
Ann Rheum Dis. 2005 Sep;64(9):1362-5.
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.
Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, Vilá LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD; LUMINA Study Group.
Arthritis Rheum. 2004 Dec;50(12):3947-57.
Risk factors for cardiovascular disease in systemic lupus erythematosus.
Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegård J.
Circulation. 2001 Oct 16;104(16):1887-93.
Epidemiology of cardiovascular disease in systemic lupus erythematosus.
Aranow C, Ginzler EM.
Lupus. 2000;9(3):166-9. Review.
Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity.
Kiani AN, Magder L, Petri M.
J Rheumatol. 2008 Jul;35(7):1300-6. Epub 2008 May 15.
Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.
Bizzaro N, Ghirardello A, Zampieri S, Iaccarino L, Tozzoli R, Ruffatti A, Villalta D, Tonutti E, Doria A.
J Thromb Haemost. 2007 Jun;5(6):1158-64.
Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies.
Gabrielli F, Alcini E, Di Prima MA, Mazzacurati G, Masala C.
Int J Cardiol. 1995 Sep;51(2):117-26.
[Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
Sarzi-Puttini P, Atzeni F, Carrabba M.
Minerva Med. 2003 Apr;94(2):63-70. Review. Italian.
Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.
Cederholm A, Svenungsson E, Stengel D, Fei GZ, Pockley AG, Ninio E, Frostegård J.
Arthritis Rheum. 2004 Sep;50(9):2869-76.
Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus.
Tso TK, Huang WN.
Rheumatol Int. 2009 May;29(7):735-42. Epub 2008 Nov 27.
Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martínez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C.
Lupus. 2004;13(12):927-33.
The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study.
Berube C, Mitchell L, Silverman E, David M, Saint Cyr C, Laxer R, Adams M, Vegh P, Andrew M.
Pediatr Res. 1998 Sep;44(3):351-6.
[Cardiovascular abnormalities in systemic lupus erythematosus patients in echocardiographic assessment].
Ostanek L, Płońska E, Peregud-Pogorzelska M, Mokrzycki K, Brzosko M, Fischer K, Fliciński J.
Pol Merkur Lekarski. 2006 Mar;20(117):305-8. Polish.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on